Applicability of a System for Fully Automated Nucleic Acid Extraction from Formalin-fixed Paraffin-embedded Sections for Routine KRAS Mutation Testing

Diagnostic Molecular Pathology

Volumn 21, Issue 2, 2012, Pages 114-119

  Lehmann, Annika ^a   Schewe, Christiane ^a   Hennig, Guido ^b   Denkert, Carsten ^a   Weichert, Wilko ^c   Budczies, Jan ^a   Dietel, Manfred ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Siemens Healthcare Diagnostics Holding GmbH   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

automated DNA extraction; FFPE; KRAS; molecular pathology; routine diagnostics

Indexed keywords

DNA; FORMALDEHYDE; K RAS PROTEIN; PARAFFIN; RNA;

ARTICLE; AUTOMATION; CANCER SCREENING; COLON; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST; DNA EXTRACTION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LUNG; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY CONTROL; RNA EXTRACTION; UTERINE CERVIX;

ADENOCARCINOMA; AUTOMATION, LABORATORY; CERVIX UTERI; COLON; COLORECTAL NEOPLASMS; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; FIXATIVES; FORMALDEHYDE; GLYCOPROTEINS; HUMANS; LIVER; LUNG; LYMPH NODES; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; PARAFFIN EMBEDDING; PREGNANCY PROTEINS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RIBOSOMAL PROTEINS; RNA; TISSUE FIXATION;

EID: 84861235413     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31823569ca     Document Type: Article

References (17)

1. Bronte G, Rizzo S, La Paglia L, et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev. 2010; 36(suppl 3):S21-S29.
2. Dempke WCM, Heinemann V. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma. Anticancer Res. 2010;30:4673-4677.
3. Wozniak A, Floris G, Debiec-Rychter M, et al. Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies. Cancer Invest. 2010;28:839-848.
4. Richmond T. The current status and future potential of personalized diagnostics: streamlining a customized process. Biotechnol Annu Rev. 2008;14:S411-S422.
5. Neumann J, Zeindl-Eberhart E, Kirchner T, et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205:858-862.
6. Baynes RD, Gansert J. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectalcancer. Am J Ther. 2009;16:554-561.
7. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
8. Lièvre A, Bachet J, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-379. (Pubitemid 351171687)
9. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol. 2009;16:196-203.
10. Koshiba M, Ogawa K, Hamazaki S, et al. The effect of formalin fixation on DNA and the extraction of high-molecular-weight DNA from fixed and embedded tissues. Pathol Res Pract. 1993;189:66-72. (Pubitemid 23117652)
11. Huijsmans CJ, Damen J, van der Linden JC, et al. Comparative analysis of four methods to extract DNA from paraffin-embedded tissues: effect on downstream molecular applications. BMC Res Notes. 2010;3:239.
12. Bohmann K, Hennig G, Rogel U, et al. RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem. 2009;55:1719-1727.
13. Dundas N, Leos NK, Mitui M, et al. Comparison of automated nucleic acid extraction methods with manual extraction. J Mol Diagn. 2008;10:311-316. (Pubitemid 352019116)
14. Hennig G, Gehrmann M, Stropp U, et al. Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem. 2010;56:1845-1853.
15. Weichert W, Schewe C, Lehmann A, et al. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics:comparison of methods and impact of histology. J Mol Diagn. 2010;12:35-42.
16. Bonomi P, Buckingham L, Coon J. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res. 2007;15(Pt 2):4606-4612.
17. Monzon FA, Ogino S, Hammond MEH, et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med. 2009;133:1600-1606.